Oncolytics Biotech (TSE:ONC) Shares Cross Below 200 Day Moving Average of $1.54

Oncolytics Biotech Inc. (TSE:ONC) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$1.54 and traded as low as C$1.35. Oncolytics Biotech shares last traded at C$1.36, with a volume of 20,600 shares traded.

Analysts Set New Price Targets

Separately, Raymond James set a C$3.00 price target on Oncolytics Biotech and gave the stock an “outperform” rating in a research report on Thursday, April 4th.

Oncolytics Biotech Trading Down 2.2 %

The company has a 50-day simple moving average of C$1.49 and a 200 day simple moving average of C$1.54. The company has a debt-to-equity ratio of 4.91, a quick ratio of 8.86 and a current ratio of 8.14. The company has a market capitalization of C$102.57 million, a P/E ratio of -3.40 and a beta of 1.49.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings data on Thursday, May 9th. The company reported C($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of C($0.12) by C$0.03. Sell-side analysts expect that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.